Department of Pain Medicine, Division of Anesthesiology, Critical Care & Pain Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Department of Neurology, The University of Texas McGovern Medical School, Houston, TX 77030, USA.
Pain Manag. 2021 May;11(3):267-276. doi: 10.2217/pmt-2020-0083. Epub 2021 Feb 3.
Pain is common in advanced cancer is often refractory to standard treatment. Ketamine has shown promise as an effective adjuvant despite conflicting reports. The aim of this retrospective was to analyze the efficacy of subanesthetic ketamine infusion in the ambulatory setting over an extended follow-up period of 3 months for symptoms related to refractory cancer pain. Forty seven patients treated with intravenous ketamine infusion for refractory cancer pain at a tertiary referral cancer center. Patients demonstrated improvement from baseline in worst, mean, current and least pain immediately after treatment (p < 0.05), worst pain 1 month after treatment (p = 0.003), and current pain (p = 0.036) and worst pain (p = 0.002) 3 months after treatment. Symptoms of quality of life were followed 1 month after treatment.
晚期癌症患者常伴有疼痛，且对标准治疗往往具有抗性。氯胺酮作为一种有效的辅助药物具有很大的应用前景，但目前报告结果存在冲突。本回顾性研究的目的是分析在 3 个月的延长随访期内，门诊环境下亚麻醉剂量氯胺酮输注对难治性癌痛相关症状的疗效。在一家三级转诊癌症中心，对 47 例难治性癌痛患者进行了静脉内氯胺酮输注治疗。患者在治疗后即刻（p < 0.05）、治疗后 1 个月（p = 0.003）、治疗后 3 个月（p = 0.036）最差疼痛和当前疼痛，以及治疗后 3 个月时最差疼痛（p = 0.002）和最小疼痛方面均较基线时有所改善。在治疗后 1 个月时还对生活质量相关症状进行了随访。
